News Quantified

BLCM – bellicum pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Form 15-12G BELLICUM PHARMACEUTICALS

Form EFFECT BELLICUM PHARMACEUTICALS

Form EFFECT BELLICUM PHARMACEUTICALS

Form EFFECT BELLICUM PHARMACEUTICALS

Form EFFECT BELLICUM PHARMACEUTICALS

Top News Gainers

12/11 Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson 40.7%

10/31 Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019 30.4%

1/15 Form 8-K BELLICUM PHARMACEUTICALS For: Jan 15 23.5%

12/31 Form 8-K BELLICUM PHARMACEUTICALS For: Dec 24 18.9%

8/23 Form 4 BELLICUM PHARMACEUTICALS For: Aug 21 Filed by: Naeve Gregory S. 15.5%

1/31 Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 10.6%

4/13 Form 8-K BELLICUM PHARMACEUTICALS For: Apr 08 10.4%

3/3 Form CT ORDER BELLICUM PHARMACEUTICALS 10.1%

8/26 Form SC 13G BELLICUM PHARMACEUTICALS Filed by: Boxer Capital, LLC 9.6%

5/15 Bellicum Pharmaceuticals to Present Updated Results for BPX-601 at the 2019 ASCO Annual Meeting 8.9%

Top News Decliners

11/6 Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update -28.5%

8/8 Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 price target on the stock. -28.0%

2/5 Bellicum Announces Reverse Stock Split -26.4%

1/24 Bellicum up 9% premarket on BPX-601 data [Seeking Alpha] -20.0%

1/24 Form SC 13D/A BELLICUM PHARMACEUTICALS Filed by: BAKER BROS. ADVISORS LP -18.2%

3/12 Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update -17.9%

1/21 Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson -17.6%

6/6 Form DEFR14A BELLICUM PHARMACEUTICALS -11.1%

7/8 Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial -10.0%

8/30 Form 4 BELLICUM PHARMACEUTICALS For: Aug 29 Filed by: Ward Shane -9.4%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day